top of page

Please check the programme regularly for changes and updates.

Sun

Sunday 22 June

14.00-15.00
Registration

15:00-15.45
Industry sponsored Symposium

Chairs:  Bernd Merkl, Troels Lillebaek

​

15:00  Inna Friesen, Borstel, Germany

Redefining the diagnosis of drug-resistant TB: Clinical validation of FluoroType® MTBDR VER2.0 and first results of tNGS workflow integration.

Bruker_Programme.png

15.45-16.15
Coffee Break​​​

16.15-16.45
Selected flash talks (5 min)
Chairs: 

​​​

16:45-19.00
Opening session
Chairs: Troels Lillebaek, Miguel Viveiros, Raquel Duarte

 

16:45

Welcome words, ESM and congress Presidents

​

Opening Keynote

17:00  Raquel Duarte,  INSA National Institute of Health and ICBAS University of Porto
GL01  Challenges in Tuberculosis Management Today

​​​​

17:45 

Gertrud Meissner Award presented by S. Niemann​​​

​

18:10 

GL02 Gardner Middlebrook Award

19.00-21.30
Networking drinks and light dinner snacks at the INSTITUTE OF HYGIENE AND TROPICAL MEDICINE

Mon

Monday 23 June

08:00-08:30
Registration

08:30-10:00

Session 1: Molecular Biology and Mycobacterial Evolution

The evolutionary history and phylogeny of mycobacteria, along with genomics for tracking transmission, resistance, and the evolution of drug resistance mechanisms provide comprehensive insights into their biology and adaptation.

 

Chairs: Christophe Sola, João Perdigão

 

08:30  Roland Brosch, Institut Pasteur, Paris

GL03  The Evolutionary History and Phylogeny of Mycobacteria

 

09:00  Dmytro Butov, Kharkiv National Medical University, Kharkiv, Ukraine

OR01  Molecular Epidemiology of Tuberculosis in Ukraine: A Nationwide Whole-Genome Sequencing Study (2020–2023)

​

09:15  Arash Ghodousi, Vita-Salute San Raffaele University, Milan

OR02  CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen

​

09:30  Faramarz Valafar, San Diego State University

OR03  Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis of M. tuberculosis complex graph pangenome

​

09:45  Nour Gharbi, EPHE, PSL University, Paris

OR04  Genome-wide association analysis of Mycobacterium tuberculosis lineage 2 reveals key factors for its enhanced epidemic success

10:00-10:30
Coffee Break

10:30-12:00
Session 2:
One Health Perspective on the Epidemiology, Environment, Lifestyle and Risk Factors for Mycobacteria Infection and Disease

The impact of aging, chronic diseases, co-infections, climate change, water quality, and microbiota on M. tuberculosis and non-tuberculous mycobacterial infections, as well as zoonotic tuberculosis in the One Health Era, highlights the need for an integrated approach addressing human, animal, and environmental health to prevent mycobacterial infection and transmission
 

Chairs: Nuno Empadinhas, Leen Rigouts


10:30  Jean-François Guégan, UMR MIVEGEC, Montpellier, France

GL04  Canonical fact versus hypothesis testing to decipher transmission of non-tuberculous and tuberculous mycobacteria
 

11:00  Camille Allam, Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux (CNR MyrMA)

OR05  Standardised protocol for the detection and quantification of nontuberculous mycobacteria in tap water and its application in investigating the source of clinical infections

​​

11:15  Margo Diricks, Research Center Borstel

OR06  Indoor water systems as reservoirs for clinically relevant non-tuberculous mycobacteria in Germany

​​

11:30  Anita Michel, University of Pretoria

OR07 TB through a One Health lens: Challenges in a rural South African setting

​​

11:45  Xenia Emilie Iversen, Statens Serum Institute, Copenhagen

OR08 Nontuberculous Mycobacteria in Denmark: Seven Decades of Clinical Occurrence 

12:00-12:45
Poster pitches - Session 1

Chair: Leen Rigouts
 
1 minute per poster (29 posters)

​

View Posters >

12:45-13:30
Lunch

13:30-14:45
Poster Session 1 

All posters with uneven numbers (P001, P003 etc)

14:45-16:15
Session 3: Host-Pathogen interactions in TB

Advances in understanding the immune response to M. tuberculosis infection, including lineage-specific drivers of differential immune response and virulence, have highlighted biomarkers of protection and susceptibility as well as potential host-directed therapies.

​

Chairs: Iñaki Comas, Margarida Saraiva

 

14:45  Mireia Coscolla,  University of Valencia
GL05  Evolutionary insights in host-pathogen compatibility of M. tuberculosisecotypes.

​

15:15  Javier Alonso del Real, Instituto de Biomedicina de Valencia - Spanish National Research Council

OR09  Mycobacterium tuberculosis trehalose synthesis pathways as key determinant of tuberculosis disease progression

​​

15:30  Tobias Dallenga, Research Center Borstel

OR10  Region-Specific Spatial Transcriptomics Reveal Distinct Immunological Functions in Human Tuberculosis Granulomas

 

15:45  Jana Schoenfeld, Research Center Borstel

OR11  Reprogramming of human macrophages in response to Mycobacterium tuberculosis complex (MTBC) infection

​​

16:00  Charlotte Genestet, International Center for Infectious Disease Research (CIRI), Lyon,

OR12  Autologous host-pathogen pairing enhances early immune responses and bacterial control in tuberculosis ex vivo granuloma model

16:15-16:45
Coffee Break

16:45-18:15
Session 4:
Clinical pathology and diagnostic advances
Diagnostic advances, artificial intelligence and new technologies relevant to clinical pathologists and laboratory professionals.

 

Chairs: Daniela Maria Cirillo, Rita Macedo


16:45  Daniela Maria Cirillo, San Raffaele Hospital, Milan

GL06  Co-development of new drugs and diagnostics to prevent drug resistance emergence

​​

17:15  Andrei Gabrielian, NIH, Washington DC

OR13  Unlocking Drug-Resistant TB Insights: Leveraging RAP’s Unique Imaging Repository for AI Validation and Beyond

​

17:30  Carsten William Höß, Serum Life Science

OR14  SIILTIBCY: A New Era in TB Diagnosis

​​

17:45  Noud Hermans, KNCV tuberculosis foundation, The Hague

OR15  Genotypic drug susceptibility testing for new tuberculosis treatment regimens: The challenge of comprehensive and reliable WHO catalogue-based sequencing data interpretation

​

18:00  Iñaki Comas, Instituto de Biomedicina de Valencia - Spanish National Research Council

OR16  Complete genomes reveal unprecedented genomic diversity of Mycobacterium tuberculosis complex from global to within-host variation

18:30
Transfer to central Lisboa for those booked on the 
guided tour

20:30
Traditional Dinner @ Museu da Cerveja
Terreiro do Paço, Ala Nascente, nº 62 a 65
1100-148 Lisboa

Tuesday 24 June

08:30-09:00
Registration

09:00-10:00

Session 5: Recent advances in research on Mycobacterial pathogenesis

Experimental infection models, ranging from vertebrates, rodents, and non-human primates to novel in vitro systems such as human granulomas, organoids, and lung-on-a-chip.

 

Chairs: Mireia Coscolla, Maria Salomé Gomes 

 

09:00  William Branchett, Francis Crick Institute, London​

GL07  Models and Mechanisms of M. tuberculosis Infection Outcome

​

09:30  Mariona Cortacans, Institut d'investigació en Ciències de la Salut Germans Trias i Pujol, Badalona

OR17  When Non-Pathogens Kill: Mycolicibacterium manresensis as a Model for Cryptic Virulence in Mycobacteria

 

09:45  Marta Arch, Institut d'investigació en Ciències de la Salut Germans Trias i Pujol, Badalona

OR18  Investigating the virulence of Mycobacterium abscessus using the Drosophila melanogaster infection model

10:00-10:25

Poster pitches - Session 2

Chair: Daniela Maria Cirillo

​

1 minute per poster (16 posters)

​

View Posters >

10:25-11:00
Coffee Break

11:00-12:30

Session 6: New generation vaccines for TB and TB diagnostics

Advances in vaccine research, including innovative adjuvants and strategies tailored to different epidemiological profiles driving the development of next-generation tuberculosis vaccines

​

Chairs: Matthias Merker, Elsa Anes

​

11:00  Helen McShane, University of Oxford   

GL08  Progress and challenges in tuberculosis vaccine development.​

​​

11:30  Patricia Cuenca Lara, CReSA, IRTA, Universitat Autònoma de Barcelona

OR19  Evaluation of immune responses elicited by respiratory mucosal vaccination strategies against TB in a goat model

​​

11:45  Kristin Kremer, KNCV Tuberculosis Foundation, The Hague

OR20  Utility of targeted Nanopore sequencing for the detection of drug-resistant tuberculosis in Kyrgyzstan

 

12:00  Paulo Bettencourt, Faculty of Medicine, Universidade Católica Portuguesa, Rio de Mouro

OR21  Immunopeptidomics for vaccines against tuberculosis

​

12:15  Oren Tzfadia, Institute of Tropical Medicine, Antwerp

OR22  Determining the genetic drivers of pathogenicity in the genus Mycobacterium

12:30-12:50

Poster pitches - Session 3

Chair: 

​

1 minute per poster (15 posters)

​

View Posters >

12:50-13:45
Lunch

13:45-15:00
Poster Session 2

All posters with an even number (P002, P004, etc)

15:00-15:45

Industry sponsored Symposium

​Chairs: Leen Rigouts 

 

15:00  Viktoria Szel, National Reference Laboratory for Mycobacteriology, Hungary

Implementation plan of the Mycobacterium RealTime Kit Vircell (MRTVircell) Assay for Detecting Mycobacterium Species in National Mycobacterium Reference Lab, Hungary.​

Vircell_Programme (1).png

15:45 - 16:15

Session 7: Therapeutic strategies for NTM and TB

Treatment of NTM focused on evidence for new drugs, including antibiotic and non-antibiotic combinations, alongside discontinuation strategies and treatment adjustments based on clinical response.

​

Chairs: Troels Lillebaek, Raquel Duarte

 

15:45  Natalie Lorent, KU Leuven

​GL09  Rethinking NTM management: new drugs, new approaches, new hope.

16:15-16:45
Coffee Break

16:45-18:15

Session 8: Therapeutic strategies for NTM and TB Part 2

 

Chairs: Daniela Maria Cirillo, Raquel Duarte

​​​

16:45  Nicola Lorè, San Raffaele Scientific Institute, Milan

OR23  Single-cell RNA sequencing shows that circulating monocytes enriched in IFN signaling are associated with nontuberculous mycobacteria pulmonary disease in cystic fibrosis 

​​​

17:00  D Moreira Sousa, Pulmonology Department, Local Health Unit Cova da Beira, Covilhã

OR24  International Consensus Framework for Managing Treatment Failure in Nontuberculous Mycobacterial Pulmonary Disease

​

17:15  Chloé Jacquet, Inserm U1070 PHAR2, Poitiers

OR25  Fidaxomicin, a potential new drug for combinatorial therapies against Mycobacterium abscessus.

​​

17:30  Simone Mok, Irish Mycobacteria Reference Laboratory, St. James’s Hospital, Dublin

OR26  Evaluation of NTM-Profiler for identification and drug resistance prediction in nontuberculous mycobacteria from whole genome sequencing data

​

17:45  Aarnoud van der Spoel, Dalhousie University, Halifax

OR27  Modelling a genetic condition that protects against tuberculosis

​​

18:00  Fabio Saliu, San Raffaele Scientific Institute, Milan

OR28  Preclinical murine models for studying lung infection and antimicrobial treatments of Nontuberculous mycobacteria

18:15
General Assembly

19:30

Social activity: Dinner and party @ Doca do Santo, 

Armazém CP – Doca de Santo Amaro

Tue
Wed

Wednesday 25 June

08.30-09:00
Registration

09.00-11.00

Session 9: Neglected mycobacterial diseases - Continuing challenges for a hopeful future

New hurdles in the fight against neglected mycobacterial diseases such as leprosy and Buruli - resistance, challenges in diagnosis, and the debate between molecular and traditional methods to better identify these often non-cultivable pathogens.

​

Chairs: Isabel Couto, Leen Rigouts

​

09:00  Leen Rigouts, Institute of Tropical Medicine, Antwerp

GL10  Neglected mycobacterial diseases - Continuing challenges for a hopeful future

 

09:30  Emmanuelle Cambau, APHP-GHU Nord & Université Paris Cité

GL11  Leprosy: back to the future

 

10:00  Conor Meehan, Nottingham Trent University

OR29  Validating a SNP calling pipeline for Mycobacterium leprae

​

10:15  Louisa Warryn, Swiss Tropical and Public Health Institute

OR30  The diagnostic potential of Mycobacterium ulcerans Mycolactone and the surface protein MUL_3720

 

10:30  Alisa Aliaga Samanez, MIVEGEC (UMR Université de Montpellier, CNRS, IRD),

OR31  Natural drivers and Human-Induced Pressures shaping the distribution of Mycobacterium ulcerans and Buruli Ulcer

 

10:45  Tim Stinear, University of Melbourne

OR32  Solving the transmission enigma of Buruli ulcer (Mycobacterium ulcerans infection)

11.00-11:30
Coffee Break

11:30-13.00

Session 10: Systems Biology Approaches to Accelerate Mycobacteriosis Drug Discovery

Emerging areas in the fight against TB and NTM including omics approaches for identifying new host and pathogen drug targets, advancements in drug delivery methods, drug discovery and repurposing pipelines for mycobacteriosis, exploration of non-antibiotic treatments, and innovations in adaptive clinical trial designs.​

​

Chairs: Miguel Viveiros, Troels Lillebaek

​

11:30  Hannu Myllykallio, Polytechnique; Palaiseau

GL12  From Abyss to Mycobacterial Drug Discovery

​​​

12:00  Pedro Duarte, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa,

OR33  Implementing large-scale genomics and genomic subtractive strategies to expand the target space in Mycobacterium tuberculosis: a strategy for improving target-based drug discovery

​​

12:15  Liliana Rodrigues, GHTM, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa,

OR34  Exploring in silico drug repurposing to develop new therapeutic alternatives for tuberculosis

​

12:30  Andrea Muscetti, San Raffaele Scientific Institute, Milan

OR35  DprE1 inhibitors and bedaquiline combination for TB treatment: in-vitro and in-silico analyses

​

12:45  Salomé Gomes, University of Porto

OR36  Improved models for drug development against non-tuberculous mycobacteria

​​

13:00-13.15

Poster Awards and Closing Ceremony

Chairs: Troels Lillebaek, Leen Rigouts

ESM Logo_White.png

Registered address:
c/o TREASURER
Matthias Merker
Parkallee 1
23845 Borstel
Germany

  • X
  • Facebook
  • LinkedIn
  • YouTube

© 2021 The European Society of Mycobacteriology

bottom of page